scholarly journals Strong antitumor efficacy of a pancreatic tumor-targeting oncolytic adenovirus for neuroendocrine tumors

2017 ◽  
Vol 6 (10) ◽  
pp. 2385-2397 ◽  
Author(s):  
Yuki Yamamoto ◽  
Masaki Nagasato ◽  
Yosei Rin ◽  
Marina Henmi ◽  
Yoshinori Ino ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Tumor Targeting ◽  
Pancreatic Tumor ◽  
Oncolytic Adenovirus ◽  
Antitumor Efficacy

scholarly journals Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of theMDR1promoter activity

Oncotarget ◽  
2015 ◽  
Vol 6 (35) ◽  
pp. 38308-38326 ◽  
Author(s):  
Bing-Hua Su ◽  
Gia-Shing Shieh ◽  
Yau-Lin Tseng ◽  
Ai-Li Shiau ◽  
Chao-Liang Wu
Keyword(s):  
Oncolytic Adenovirus ◽  
Antitumor Efficacy

scholarly journals The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus

2010 ◽  
Vol 10 (3) ◽  
pp. 242-250 ◽  
Author(s):  
Lian Li Xiao ◽  
Yu Mei Wu ◽  
Jing Qian ◽  
Yuan Tan ◽  
Guo Liang Xie ◽  
...  
Keyword(s):  
Oncolytic Adenovirus ◽  
Antitumor Efficacy

Neuroendocrine tumor targeting: Study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model

2002 ◽  
Vol 98 (6) ◽  
pp. 930-937 ◽  
Author(s):  
Sylvie Froidevaux ◽  
Alex N. Eberle ◽  
Martine Christe ◽  
Lazar Sumanovski ◽  
Axel Heppeler ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Tumor Targeting ◽  
Pancreatic Tumor ◽  
Tumor Model

scholarly journals A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel

Oncotarget ◽  
2017 ◽  
Vol 8 (14) ◽  
pp. 22700-22715 ◽  
Author(s):  
Ana Mato-Berciano ◽  
Giulia Raimondi ◽  
Maria Victoria Maliandi ◽  
Ramon Alemany ◽  
Lluis Montoliu ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Pancreatic Tumor ◽  
Oncolytic Adenovirus ◽  
Anticancer Effects

Potent Antitumor Efficacy of ST13 for Colorectal Cancer Mediated by Oncolytic Adenovirus via Mitochondrial Apoptotic Cell Death

2008 ◽  
Vol 19 (4) ◽  
pp. 343-353 ◽  
Author(s):  
Min Yang ◽  
Xin Cao ◽  
Ming Can Yu ◽  
Jin Fa Gu ◽  
Zong Hou Shen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cell Death ◽  
Apoptotic Cell ◽  
Oncolytic Adenovirus ◽  
Apoptotic Cell Death ◽  
Antitumor Efficacy

scholarly journals Antiangiogenic Arming of an Oncolytic Vaccinia Virus Enhances Antitumor Efficacy in Renal Cell Cancer Models

2009 ◽  
Vol 84 (2) ◽  
pp. 856-866 ◽  
Author(s):  
Kilian Guse ◽  
Marta Sloniecka ◽  
Iulia Diaconu ◽  
Kathryn Ottolino-Perry ◽  
Nan Tang ◽  
...  
Keyword(s):  
Growth Factor ◽  
Vaccinia Virus ◽  
Renal Cell ◽  
Tumor Targeting ◽  
Cell Cancer ◽  
Extramedullary Hematopoiesis ◽  
Antitumor Efficacy ◽  
Antiangiogenic Effect ◽  
Cancer Models ◽  
Systemic Application

ABSTRACT Oncolytic vaccinia viruses have shown compelling results in preclinical cancer models and promising preliminary safety and antitumor activity in early clinical trials. However, to facilitate systemic application it would be useful to improve tumor targeting and antitumor efficacy further. Here we report the generation of vvdd-VEGFR-1-Ig, a targeted and armed oncolytic vaccinia virus. Tumor targeting was achieved by deletion of genes for thymidine kinase and vaccinia virus growth factor, which are necessary for replication in normal but not in cancer cells. Given the high vascularization typical of kidney cancers, we armed the virus with the soluble vascular endothelial growth factor (VEGF) receptor 1 protein for an antiangiogenic effect. Systemic application of high doses of vvdd-VEGFR-1-Ig resulted in cytokine induction in an immunocompromised mouse model. Upon histopathological analysis, splenic extramedullary hematopoiesis was seen in all virus-injected mice and was more pronounced in the vvdd-VEGFR-1-Ig group. Analysis of the innate immune response after intravenous virus injection revealed high transient and dose-dependent cytokine elevations. When medium and low doses were used for intratumoral or intravenous injection, vvdd-VEGFR-1-Ig exhibited a stronger antitumor effect than the unarmed control. Furthermore, expression of VEGFR-1-Ig was confirmed, and a concurrent antiangiogenic effect was seen. In an immunocompetent model, systemic vvdd-VEGFR-1-Ig exhibited superior antitumor efficacy compared to the unarmed control virus. In conclusion, the targeted and armed vvdd-VEGFR-1-Ig has promising anticancer activity in renal cell cancer models. Extramedullary hematopoiesis may be a sensitive indicator of vaccinia virus effects in mice.

Sign in / Sign up

Export Citation Format

Share Document